Skip to main content

Table 2 Univariate analysis of survival for patients with ANPC

From: Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma

  All population Cycles <4 population Cycles > =4 population
Variable OS DMFS OS DMFS OS DMFS
Leucopenia       
Mild VS Absent      
HR(95 %CI) 0.70(0.57-0.86) 0.79(0.63-0.98) 0.73(0.57-0.92) 0.87(0.66-1.14) 0.56(0.38-0.86) 0.56(0.37-0.86)
p 0.001 0.038 0.009 0.309 0.007 0.008
Severe VS Absent      
HR(95 %CI) 0.77(0.60-0.97) 1.01(0.78-1.31) 0.86(0.63-1.16) 1.10(0.79-1.54) 0.59(0.38-0.90) 0.73(0.46-1.14)
P 0.030 0.927 0.320 0.554 0.016 0.166
Mild VS Severe      
HR(95%CI) 0.91(0.76-1.09) 0.77(0.64-0.93) 0.85(0.66-1.08) 0.78(0.61-1.02) 0.98(0.75-1.28) 0.77(0.58-1.09)
p 0.314 0.007 0.191 0.069 0.887 0.058
Gender       
HR(95 %CI) 0.62(0.51-0.75) 0.69(0.57-0.84) 0.63(0.50-0.79) 0.71(0.55-0.91) 0.61(0.45-0.84) 0.67(0.49-0.2)
P <0.001 <0.001 <0.001 0.007 0.002 0.015
Age       
HR(95 %CI) 1.84(1.59-2.14) 1.09(0.93-1.27) 1.93(1.59-2.34) 1.14(0.94-1.39) 1.73(1.36-2.19) 1.01(0.77-1.30)
P <0.001 0.304 <0.001 0.191 <0.001 0.941
T-classification      
HR(95 %CI) 1.27(1.14-1.40) 1.09(0.99-1.22) 1.27(1.11-1.45) 1.11(0.96-1.27) 1.26(1.07-1.49) 1.08(0.91-1.27)
P <0.001 0.092 0.001 0.157 0.007 0.375
N-classification      
HR(95CI) 1.56(1.43-1.70) 1.65(1.50-1.81) 1.70(1.51-1.90) 1.75(1.54-1.97) 1.39(1.21-1.60) 1.52(1.32-1.76)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Radiotherapy       
HR(95 %CI) 0.80(0.68-0.94) 0.91(0.76-1.08) 0.88(0.70-1.10) 1.03(0.82-1.30) 0.69(0.54-0.89) 0.75(0.58-0.97)
P 0.008 0.273 0.264 0.764 0.005 0.030
  1. Abbreviations: OS: overall survival; DMFS: distant metastasis-free survival; HR: hazard ratio; CI: confidence interval; ANPC: advanced nasopharyngeal carcinoma